CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that Steve Pakola, M.D. has been appointed as the company’s first Chief Medical Officer. Dr. Pakola will lead the advancement of Aerpio’s development pipeline, including lead therapeutic candidate, AKB-9778. Dr. Pakola will report to Aerpio’s President and CEO Joseph Gardner, and his appointment is effective immediately. “Steve brings 20
A 72-year-old Armenian woman was referred to the oculoplastics clinic at the New England Eye Center for evaluation of bilateral ptosis. She noticed gradual onset of drooping eyelids over the course of many years.The patient’s medical history was significant only for medically well controlled hypertension and hypercholesterolemia. She was pseudophakic and had lattice corneal dystrophy. Of note, two of her children had lattice corneal dystrophy. Her brother and two children also had similar ptosis. She denied trauma, eye rubbing or chronic contact lens wear. She had no other infectious, neoplastic or inflammatory conditions or risk factors.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company’s lead product candidate, ENV515 (travopro…
NIH-funded study shows success in targeting mitochondrial DNA in miceResearchers funded by the National Institutes of Health have developed a novel mouse model for the vision disorder Leber…
TUCSON, Ariz.–(BUSINESS WIRE)–Photometrics, a manufacturer of high performance scientific cameras for life science applications, today announces the release of its new sCMOS camera, the Photometrics Prime. Prime is the first 4.2 Megapixel scientific CMOS camera available for life science research that actively defeats the negative impact of Poisson noise in low light images. The camera packs a formidable FPGA-based Embedded Signal Processing engine, ESP™, that enables powerful signal restorat
Researchers funded by the National Institutes of Health have developed a novel mouse model for the vision disorder Leber hereditary optic neuropathy (LHON), and found that they can use gene therapy to improve visual function in the mice. LHON is one of…